Aktuelle aspekte der onkologischen immuntherapie

[1]  W. Terry.  Immunotherapy of malignant melanoma. , 1980, The New England journal of medicine.

[2]  G. Math.  Systemic active immunotherapy is shifting from the middle ages to a renaissance period: I. The multiplication of randomized trials showing significant effect of active immunotherapy on residual minimal disease , 1978 .

[3]  P. Schlag,et al.  Untersuchungen zum zellulären Immunstatus bei Normalpersonen, Nichtmalignom- und Malignompatienten , 1978 .

[4]  J. Roboz,et al.  Specific immunotherapy with neuraminidase-modified leukemic cells: experimental and clinical trials. , 1977, The Medical clinics of North America.

[5]  W. Amery.  DOUBLE‐BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER , 1976, Annals of the New York Academy of Sciences.

[6]  D. Morton,et al.  BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma. , 1976, The Medical clinics of North America.

[7]  E. Mickiewicz,et al.  LEVAMISOLE IN ADVANCED HUMAN BREAST CANCER , 1976, The Lancet.

[8]  I. Penn.  Occurrence of cancer in immune deficiencies , 1974, Current problems in cancer.

[9]  J. Forbes,et al.  Correlation Between Nonspecific Immune Competence and Clinical Outcome of Breast, Colon, and Stomach Cancer , 1979 .

[10]  H. Wanebo,et al.  Immunocompetence Testing in Patients with One of the Common Operable Cancer — A Review , 1979 .

[11]  E. Giacobini,et al.  Molecular forms of acetylcholinesterase in the ciliary ganglion and iris of the chick. Developmental changes and effects of axotomy. , 1978, Developmental neuroscience.

[12]  C. Melief,et al.  Immunocompetence and Malignancy , 1975 .

[13]  Old Lj,et al.  Current enigmas in cancer research. , 1973 .